Mazor Robotics Ltd – (NASDAQ:MZOR)’s share price hit a new 52-week high on Friday . The stock traded as high as $24.79 and last traded at $24.50, with a volume of 109,124 shares trading hands. The stock had previously closed at $23.50.

Several brokerages have weighed in on MZOR. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics Ltd – in a research note on Thursday, July 7th. Wells Fargo & Co. upgraded Mazor Robotics Ltd – from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 19th. Zacks Investment Research upgraded Mazor Robotics Ltd – from a “sell” rating to a “hold” rating in a research note on Tuesday, June 14th. Sterne Agee CRT cut Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 31st. Finally, Barclays PLC lifted their target price on Mazor Robotics Ltd – from $16.00 to $23.00 and gave the stock an “overweight” rating in a research note on Thursday, July 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Mazor Robotics Ltd – presently has an average rating of “Buy” and a consensus target price of $25.00.

The company has a 50 day moving average price of $20.49 and a 200-day moving average price of $14.12. The firm’s market cap is $529.04 million.

Mazor Robotics Ltd – (NASDAQ:MZOR) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The firm earned $8.30 million during the quarter, compared to analysts’ expectations of $8.51 million. Mazor Robotics Ltd -‘s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.05) earnings per share. On average, equities analysts predict that Mazor Robotics Ltd – will post ($0.63) earnings per share for the current fiscal year.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.